What We Do

Our “protection pill,” NHPN-1010, is one of our therapeutic technologies and represents a potential and hopeful answer to noise or blast-induced hearing loss. Possible indications for NHPN-1010 include, but are not limited to, noise-induced hearing loss, blast-induced hearing loss, tinnitus, hyperacusis, and protection from degenerative hearing loss.

The pill has passed Phase I clinical trials for safety and was found to be safe and well-tolerated. The next steps are for a pharmaceutical company to further clinical development through Phase III clinical trials for each indication.

For updates on the status of NHPN-1010's clinical development, please contact Elaine Hamm at ehamm@ascendbioventures.com. If you would like additional information from Hough Ear Institute, please reach out to info@houghear.org.